InvestorsHub Logo
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

Re: skyisnotthelimit post# 1032

Monday, 07/19/2010 4:17:49 PM

Monday, July 19, 2010 4:17:49 PM

Post# of 27413
We come closser to the enrollment of patient number 80 and finally of patient number 100.
Every day that passes the probability that the share price breaks .10$/share gets bigger, because of new buyers holding their shares with them for the long term and because of possible institutions buying a position into ctso.

Remember this:
keywords:
1° limited competition (only Xigris is approved to treat sepsis, but has questionable efficacy and safety)
2°critical care play and therefore an easy market penetration
3° reimbursement friendly
high margin disposable device in an under-served multi-billion dollar market with strategically important technology



The Company has leading, patented technology backed by strong science and a highly profitable business model. We believe CytoSorb™ has the potential to be a blockbuster therapy that can be sold throughout the world as a treatment for sepsis and other diseases exacerbated by cytokine storm. If successful, these characteristics position the Company well for growth and future value creation for shareholders. Also, we continue to unlock the value of our underlying polymer platform technology through the ability to modify it for other medical applications, further broadening our pipeline and potential for out-licensing opportunities.

http://02c390e.netsolhost.com/invest.htm
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News